After exercising 9,500 options, a CEO family trust sells 9,500 United Therapeutics (UTHR) shares.
Martine A. Rothblatt, Chairperson & CEO of United Therapeutics (UTHR), through a family trust, exercised 9,500 stock options at $117.76 per share and subsequently sold 9,500 common shares. These transactions, executed on October 1, 2026, were part of a pre-arranged Rule 10b5-1 trading plan adopted in November 2025. The sales occurred across 19 transactions with weighted-average prices ranging from $560.05 to $584.6622 per share.
CEO family trusts sell 7,580 shares as United Therapeutics (UTHR) reports a 9,500-option exercise.
Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp. (UTHR), reported that family trusts exercised 9,500 stock options and acquired 9,500 common shares on September 30, 2026. Concurrently, these family trusts sold 7,580 common shares, actions taken pursuant to a pre-arranged Rule 10b5-1 plan adopted in November 2025. The transaction involved an exercise price of $117.76 per share for the options, resulting in approximately $3.93 million in gross sale proceeds and an approximate exercise cost of $1.12 million.
An 8,300-share sale followed an option exercise by United Therapeutics (UTHR) counsel Paul A. Mahon.
United Therapeutics (UTHR) EVP and General Counsel Paul A. Mahon exercised stock options for 8,300 shares at $146.03 on October 1, 2026. He subsequently sold all 8,300 shares in multiple trades under a pre-arranged 10b5-1 plan, with gross sale proceeds of approximately $4.69 million, resulting in an estimated pre-tax spread of $3.48 million. After these transactions, his reported holdings included 39,240 stock options and 45,172 common shares.
United Therapeutics Stock Rises Following Federal Court Patent Victory Over Liquidia
Shares of United Therapeutics Corp. are rising after a federal court ruled in its favor in a patent infringement lawsuit against Liquidia Corp. The court found that Liquidia induced infringement of United Therapeutics' patent related to inhaled treprostinil for pulmonary hypertension, leading to potential withdrawal of Liquidia's Yutrepia from the U.S. market for that indication and a BTIG analyst upgrade for United Therapeutics.
United Therapeutics Corporation wins Yutrepia PH‑ILD patent ruling
United Therapeutics Corporation won a patent infringement ruling against Liquidia Corporation regarding the marketing of Yutrepia for PH-ILD. A Delaware court found Liquidia induced infringement of United's inhaled treprostinil patent, leading to a significant increase in United Therapeutics' stock and a sharp decline for Liquidia. The ruling could lead to the withdrawal of Yutrepia's approval for PH-ILD and potential monetary damages for United Therapeutics.
United Therapeutics (UTHR) Moves 12.6% Higher: Will This Strength Last?
United Therapeutics (UTHR) shares surged 12.5% following a Delaware court ruling that Liquidia's Yutrepia infringes on two of UTHR's patents, potentially reducing competition for its Tyvaso products. Despite this stock jump, the company faces expectations of a 10.9% decrease in quarterly earnings year-over-year and a 0.9% drop in revenues, with earnings estimates revised 1.4% lower over the last 30 days. The article questions whether the recent strength in UTHR's stock can be sustained given these financial projections and its current Zacks Rank of #3 (Hold).
Liquidia shares crater after court rules for United Therapeutics
Liquidia Corp shares significantly dropped after a U.S. District Court in Delaware ruled that the company infringed on two patent claims held by United Therapeutics Corp. The court found claims 1 and 14 of U.S. Patent No. 11,826,327, related to treating pulmonary hypertension with interstitial lung disease using inhaled treprostinil, were valid and infringed. Liquidia plans to appeal the decision and will submit a supplement to YUTREPIA's New Drug Application to the FDA to remove the PH-ILD indication from its label.
United Therapeutics jumps 13% on court ruling (UTHR:NASDAQ)
Shares of United Therapeutics (UTHR) rallied almost 13% after a court ruling favored them in a patent dispute against Liquidia Corp. regarding the Yutrepia drug. This ruling was deemed significantly positive for United Therapeutics, while Liquidia's stock dropped over 50%. The article also notes analyst bullishness due to a strong FDA pipeline and positive legal outcome for UTHR.
A CEO’s trust exercises options and sells 9,500 United Therapeutics (UTHR) shares under a trading plan.
Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corporation (UTHR), had a family trust exercise 9,500 stock options and sell the resulting 9,500 common shares on September 29, 2026. These transactions, executed under a pre-arranged 10b5-1 trading plan adopted in November 2025, involved an exercise price of $117.76 per share and sales at varying prices, with approximate gross sale proceeds of $4.54 million. Following these transactions, the trust's reported option position was 337,910 options, along with directly held common shares and shares held by Rothblatt’s spouse.
United Therapeutics Corp Stock (UTHR) Moved Up by 12.20% on Sep 30: Key Drivers Unveiled
United Therapeutics Corp (UTHR) stock rose 12.20% on September 30, driven by market sentiment rebound, strong financial fundamentals, and aggressive capital allocation. The company completed a $2 billion share buyback program and received FDA acceptance for nebulized Tyvaso and ralinepag filings, indicating future growth potential. Despite competitive concerns and analyst sell ratings, institutional confidence remains high due to substantial share reduction and expanding disease indications.
Why Is United Therapeutics (UTHR) Stock Rocketing Higher Today
Shares of biotechnology company United Therapeutics (UTHR) jumped 13.6% after a federal court ruled that competitor Liquidia Corporation infringed on patent claims related to United Therapeutics' inhaled treprostinil treatments. The court found claims 1 and 14 of U.S. Patent No. 11,826,327 to be valid and infringed by Liquidia's Yutrepia. This positive news for United Therapeutics comes shortly after Goldman Sachs initiated coverage of the stock with a Sell rating.
After exercising options, a family trust sold 9,500 United Therapeutics (UTHR) shares under a trading plan.
A family trust associated with United Therapeutics Chairperson & CEO Martine A. Rothblatt exercised 9,500 stock options and subsequently sold the resulting 9,500 common shares. These transactions, executed on September 28, 2026, were part of a pre-arranged Rule 10b5-1 trading plan adopted in November 2025. The sales were made at weighted-average prices ranging from $472.4274 to $486.0050 per share, with an exercise price of $117.76 per share.
After exercising stock options, the CEO’s family trust sold 9,500 United Therapeutics (UTHR) shares.
Martine A. Rothblatt, Chairperson & CEO of United Therapeutics (UTHR), reported that a family trust exercised 9,500 stock options and subsequently sold 9,500 common shares on September 25, 2026. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted in November 2025. The sales resulted in approximate gross proceeds of $4.52 million and a pre-tax spread of $3.40 million.
United Therapeutics Corporation (UTHR) stock price, news, quote and history
This article provides a detailed overview of United Therapeutics Corporation (UTHR), including its stock performance, key financial metrics, and product portfolio. It highlights the company's focus on developing treatments for chronic and life-threatening diseases, particularly pulmonary arterial hypertension, and its ventures into xenotransplantation. The report also includes analyst insights, recent earnings trends, and a comparison of UTHR's returns against the S&P 500 benchmark.
Form 4 United Therapeutics Corporation For: 26 September By Investing.com
This article announces a Form 4 filing for United Therapeutics Corporation (UTHR) regarding activity on September 26. The brief piece includes the stock ticker and its performance on the day of publication.
After exercising stock options, the CEO's family trust sold 9,500 United Therapeutics (UTHR) shares.
A family trust associated with United Therapeutics Corp. Chairperson & CEO Martine A. Rothblatt exercised 9,500 stock options and subsequently sold 9,500 common shares on September 24, 2026. The options were exercised at $117.76 per share, and the common shares were sold at prices ranging from $469.7352 to $480.3300 per share, all conducted under a pre-arranged Rule 10b5-1 plan. Following these transactions, the trust holds 366,410 options and 628,049 common shares.
A Look at United Therapeutics Corp (UTHR) After 3.5% Decline -- GF Value $427.97 vs Price $472.21
United Therapeutics Corp (UTHR) shares recently declined by 3.5% to $472.21, placing the stock above its GF Value™ of $427.97, suggesting it is overvalued by approximately 10.3%. Despite this overvaluation, UTHR boasts a strong GF Score™ of 94/100, with perfect scores in financial strength and high marks in profitability and growth, yet a lower valuation rank of 6/10. Insider selling totaling $1,406.4 million over the past year, coupled with a mixed sentiment among gurus, suggests caution for investors despite the company's robust fundamentals.
Why United Therapeutics (UTHR) Shares Are Falling Today
United Therapeutics (UTHR) shares fell 4% after Goldman Sachs initiated coverage with a Sell rating, causing some investors to reduce their positions. Despite this, the company had a significant gain earlier in the year due to positive results from its TETON-1 pivotal study for Tyvaso. The stock is down 5.2% year-to-date but has shown strong long-term growth, with a $1,000 investment five years ago now worth $2,414.
United Therapeutics Falls as Goldman Sachs Sets $321 Price Target
United Therapeutics' shares declined after Goldman Sachs issued a Sell rating and a $321 price target, citing overinflated expectations for its future growth. Goldman Sachs expressed concerns about the commercial viability of new treatments and the ability of the company's pipeline to offset current business pressures. The firm also assigned a Sell rating to Sagimet Biosciences due to commercial challenges with its drug candidate.
Why United Therapeutics (UTHR) Shares Are Falling Today
Shares of United Therapeutics (UTHR) fell 4% after Goldman Sachs initiated coverage with a Sell rating, leading to a dip in the biotechnology company's stock. Despite the current drop, the stock has shown significant gains over a five-year period, and a recent positive clinical trial for its drug Tyvaso suggests potential underlying strength.
Goldman Sachs initiates United Therapeutics stock with sell rating
Goldman Sachs has initiated coverage on United Therapeutics (NASDAQ:UTHR) with a Sell rating and a price target of $321, citing a potential 34% downside. The firm raised concerns about the commercial opportunity for upcoming launches, particularly nebulized Tyvaso, and noted that the stock appears overvalued based on its price-to-earnings ratio compared to its 10-year median. This follows a mixed Q2 2026 earnings report and a lowered price target from BofA Securities due to revenue shortfalls.
United Therapeutics Corporation (UTHR) stock price, news, quote and history
This article provides a comprehensive overview of United Therapeutics Corporation (UTHR), including its current stock price, recent news, historical data, and financial performance. It details the company's product portfolio for treating chronic and life-threatening diseases, particularly pulmonary arterial hypertension, and highlights its financial metrics, analyst ratings, and comparative performance against the S&P 500.
Under a pre-arranged plan, United Therapeutics (UTHR) CEO’s family trusts exercise 9,500 options and sell the shares.
Family trusts associated with Martine Rothblatt, Chairperson & CEO of United Therapeutics (UTHR), exercised 9,500 stock options at $117.76 per share and subsequently sold the resulting 9,500 common shares in ten separate transactions on September 22, 2026. The sales, executed at weighted-average prices between $489.6121 and $499.0681, were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. Following these transactions, the trusts hold 385,410 stock options and a significant number of common shares.
United Therapeutics CEO Rothblatt sells $4.7m in stock By Investing.com
Martine A. Rothblatt, CEO of United Therapeutics Corp. (NASDAQ:UTHR), sold approximately $4.7 million worth of company stock on September 21, 2026, after exercising stock options. These transactions were executed via a pre-arranged 10b5-1 trading plan. Despite the sale, Rothblatt maintains significant indirect holdings in the company.
United Therapeutics CEO Rothblatt sells $4.7m in stock
Martine A. Rothblatt, CEO of United Therapeutics Corp. (NASDAQ: UTHR), sold approximately $4.7 million worth of company stock on September 21, 2026, after exercising stock options. The transactions were conducted under a pre-arranged 10b5-1 trading plan. This sale occurred shortly after the company reported mixed Q2 2026 earnings, with an earnings beat but a revenue miss, and a lowered price target from BofA Securities due to revised Tyvaso sales guidance.
United Therapeutics (UTHR) CEO sells shares at nearly $500 each
United Therapeutics (UTHR) CEO Martine Rothblatt, through family trusts, exercised options for 9,500 shares at $117.76 each and subsequently sold all shares at weighted-average prices between $492.97 and $496.62 per share on September 21, 2026. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. After the sale, the trusts still hold 394,910 stock options.
United Therapeutics CEO Rothblatt sells $4.7m in UTHR shares By Investing.com
Martine A. Rothblatt, CEO of United Therapeutics Corp. (NASDAQ: UTHR), sold company shares worth approximately $4.7 million on September 18, 2026, after exercising stock options. The transactions were executed under a pre-arranged 10b5-1 trading plan. Despite the CEO's sale, InvestingPro Tips indicate aggressive share buybacks and a strong financial position for the biotechnology company, though its stock is considered slightly overvalued.
CEO stock sale near $500 a share was preplanned, United Therapeutics (UTHR) says
United Therapeutics CEO Martine A. Rothblatt exercised 9,500 stock options and subsequently sold the shares for approximately $4.70 million on September 18, 2026. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted in November 2025. The sales occurred at weighted average prices between $492 and $498 per share, following the exercise of options at $117.76 per share.
United Therapeutics (NASDAQ: UTHR) general counsel sells shares near $500
United Therapeutics (UTHR) Executive Vice President and General Counsel Paul A. Mahon exercised employee stock options and sold 8,300 resulting shares on September 17, 2026. The shares were sold at prices ranging from $495.09 to $501.61, generating approximately $4.13 million in gross proceeds. This transaction was executed under a pre-arranged Rule 10b5-1 trading plan established on August 11, 2025.
United Therapeutics Insider Sold Shares Worth $4,712,580, According to a Recent SEC Filing
A recent SEC filing revealed that an insider at United Therapeutics Corporation sold shares valued at $4,712,580. This transaction occurred on September 18, 2026, as reported by MT Newswires. United Therapeutics is a biotechnology company specializing in treatments for chronic and life-threatening conditions.
United Therapeutics CEO Martine Rothblatt sells $4.7m in shares By Investing.com
Martine A. Rothblatt, CEO of United Therapeutics Corp., sold approximately $4.76 million worth of common stock on September 11, 2026, after exercising stock options. These transactions were part of a pre-arranged 10b5-1 trading plan. The company recently reported mixed Q2 2026 earnings, with EPS beating expectations but revenue falling short, leading to a revised price target from BofA Securities.
United Therapeutics unveils major lung, heart data
United Therapeutics recently presented significant Phase 3 data in Munich and Barcelona concerning treatments for pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF). The results highlighted improvements with ralinepag for PAH patients, especially those with connective tissue disease, and nebulized treprostinil for IPF, showing improved lung function and fewer flare-ups with dose-dependent benefits. The company also introduced PHINDER, a preliminary screening tool suggesting limitations in current echocardiography for pulmonary hypertension in interstitial lung disease patients.
United Therapeutics Moves to Complete Its $2 Billion Buyback, Betting the Market Is Underpricing Its Pipeline
United Therapeutics announced an accelerated share repurchase (ASR) agreement with Citibank to complete its previously authorized $2 billion buyback program, repurchasing approximately $477.6 million in common stock. Chairperson and CEO Martine Rothblatt stated this move reflects the company's belief that its pipeline's potential is currently undervalued by the market, with significant growth drivers expected soon. Upon completion, the company will have returned $4 billion to shareholders over 2.5 years, demonstrating confidence in its future.
United Therapeutics (UTHR) Sets $477.6 Million Buyback. Can Pipeline Funding Keep Pace?
United Therapeutics (UTHR) has committed $477.6 million to an accelerated share repurchase, bringing total capital returned to approximately $4 billion over two and a half years. While the company has substantial liquidity and continues investment in research and acquisitions, concerns exist regarding whether commercial cash generation can support construction, pipeline launches, and future investments without restricting financial flexibility. The article weighs the bull case of robust cash flow and pending FDA reviews against the bear case of substantial outflows for buybacks, acquisitions, and facility construction, concluding that settlement terms and liquidity will determine the impact on shareholder value.
United Therapeutics CEO Martine Rothblatt sells $4.7m in stock
Martine A. Rothblatt, CEO of United Therapeutics Corp., sold 9,500 shares of company stock worth $4.74 million on September 8, 2026, while simultaneously exercising stock options for the same number of shares for $1.12 million, all under a pre-arranged 10b5-1 trading plan. Following these transactions, her indirect beneficial ownership stands at 324,443 shares. This comes after United Therapeutics reported mixed Q2 2026 financial results, with earnings exceeding estimates but revenue missing expectations, leading BofA Securities to lower its price target.
United Therapeutics CEO Martine Rothblatt sells $4.7m in stock By Investing.com
Martine A. Rothblatt, CEO of United Therapeutics Corp. (NASDAQ:UTHR), sold approximately $4.74 million worth of stock and simultaneously exercised stock options valued at $1.12 million on September 8, 2026, under a pre-arranged 10b5-1 trading plan. These transactions altered her indirect beneficial ownership, with InvestingPro indicating the company is currently overvalued. The company also recently reported mixed Q2 2026 financial results, missing revenue forecasts, which led BofA Securities to lower its price target and maintain a Neutral rating.
United Therapeutics CEO Martine Rothblatt sells $4.7m in stock By Investing.com
Martine A. Rothblatt, CEO of United Therapeutics Corp. (NASDAQ:UTHR), sold 9,500 shares for approximately $4.74 million and concurrently acquired the same number of shares by exercising stock options valued at $1.12 million. These transactions, executed under a pre-arranged 10b5-1 trading plan, have left Ms. Rothblatt with substantial indirect beneficial ownership and derivative securities. InvestingPro suggests the company is overvalued, while recent Q2 2026 earnings showed a revenue miss despite beating EPS estimates, leading to a revised price target from BofA Securities.
United Therapeutics Corporation Announces Accelerated Share Repurchase Agreement for Remainder of $2.0 Billion Authorization
United Therapeutics Corporation has announced an Accelerated Share Repurchase (ASR) agreement with Citibank, N.A. for approximately $477.6 million, utilizing the remaining portion of its $2.0 billion share repurchase authorization. This move follows previous ASR agreements totalling $1.5 billion and open-market purchases of $22.4 million in Q3 2026. The company's CEO, Martine Rothblatt, stated that the decision reflects confidence in United Therapeutics' future growth drivers and current stock undervaluation, aiming to return $4 billion to shareholders within approximately 2.5 years upon completion of this additional repurchase.
Merrimack Anheuser-Busch Property purchased by United Therapeutics Corporation
Biotechnology firm United Therapeutics Corporation has acquired the former Anheuser-Busch brewery site in Merrimack, New Hampshire, for $47 million. This transaction secures a significant 300-acre industrial parcel and marks a major transition for the site which previously housed a large brewing operation. United Therapeutics, known for developing therapies for rare conditions and pioneering bioengineered organ manufacturing, is expected to bring hundreds of high-paying jobs to the region.
United Therapeutics Corporation Announces FDA Acceptance of Supplemental New Drug Application for Nebulized Tyvaso® to Treat Idiopathic Pulmonary Fibrosis
United Therapeutics Corporation announced that the FDA has accepted its supplemental New Drug Application (sNDA) for nebulized Tyvaso (treprostinil) Inhalation Solution to treat idiopathic pulmonary fibrosis (IPF). The company expects the FDA's review to conclude in late April 2027. This sNDA is based on positive results from the phase 3 TETON-1 and TETON-2 studies, which demonstrated statistically significant superiority over placebo in improving forced vital capacity and other key secondary endpoints for IPF patients.
Anheuser-Busch plant in Merrimack sold to United Therapeutics for $47.5M
United Therapeutics Corp. has purchased the former Anheuser-Busch brewery in Merrimack, New Hampshire, for $47.5 million, further expanding its investment in the state's life science industry. The Maryland-based biotechnology company, which specializes in organ transplantation technologies, acquired the nearly 300-acre property after Anheuser-Busch ceased brewing operations there. This acquisition strengthens United Therapeutics' presence in New Hampshire, where it already operates a significant research and development center in Manchester.
Former Anheuser-Busch plant sold to United Therapeutics
The former Anheuser-Busch plant in Merrimack, N.H., has been sold to United Therapeutics Corporation, a biotech company specializing in organ transplantation pharmaceuticals and technologies. This acquisition significantly expands United Therapeutics' footprint in Southern New Hampshire, adding a nearly 300-acre site to its existing operations, which include a research and development center in Manchester. The closure of the Anheuser-Busch plant was announced in December.
Stewartville's xenotransplant pig facility is ready for animals
United Therapeutics Corp. has completed its $110 million "Designated Pathogen-Free" facility in Stewartville, Minnesota, designed to raise gene-edited pigs for human organ transplantation. The facility, named the Thomas E. Starzl Xenograft Production Facility, has a capacity for 150 animals and will be operated by a team of about 25 people using stringent sterile conditions. United Therapeutics aims to gain FDA approval for pig-to-human transplants by the end of the decade, building on its success with the first pig-to-human heart and kidney transplants.
United Therapeutics (NASDAQ: UTHR) CEO sells 9,500 shares in preset plan
Martine A. Rothblatt, Chairperson & CEO of United Therapeutics (UTHR), conducted an insider transaction on August 24, 2026, through family trusts. This involved exercising 9,500 stock options at $135.42 per share and simultaneously selling 9,500 common shares at weighted-average prices between $509 and $513. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted in November 2025.
United Therapeutics (NASDAQ: UTHR) CEO sells 9,500 under 10b5-1 plan
United Therapeutics (UTHR) CEO Martine A. Rothblatt exercised 9,500 stock options at $135.42 per share and subsequently sold the acquired 9,500 common shares in multiple transactions, with prices ranging from $512.51 to $528.02 per share, on August 21, 2026. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. Following these transactions, family trusts associated with Rothblatt still hold 84,910 stock options and significant indirect common stock holdings, in addition to her direct holdings of 40,513 shares.
FDA accepts United Therapeutics' ralinepag NDA for PAH
The US FDA has accepted United Therapeutics' New Drug Application (NDA) for ralinepag, an investigational prostacyclin IP receptor agonist for pulmonary arterial hypertension (PAH), setting a PDUFA target action date of June 24, 2027. The filing is supported by Phase III ADVANCE OUTCOMES study results showing ralinepag significantly reduced the risk of clinical worsening events by 55% compared to placebo. If approved, ralinepag would be the first once-daily oral prostacyclin IP receptor agonist available for PAH, offering a potential new treatment option.
A once-daily pill cut PAH worsening risk 55%; FDA review is underway
United Therapeutics announced that the FDA has accepted its New Drug Application (NDA) for ralinepag, a once-daily oral prostacyclin, to treat Pulmonary Arterial Hypertension (PAH). The NDA is supported by positive results from the phase 3 ADVANCE OUTCOMES study, which showed ralinepag significantly reduced the risk of clinical worsening by 55% compared to placebo and improved secondary endpoints like NT-proBNP levels and six-minute walk distance. The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of June 24, 2027, for its decision.
United Therapeutics (NASDAQ: UTHR) CEO sale part of 1,734,410-option 10b5-1 plan
United Therapeutics (NASDAQ: UTHR) CEO Martine A. Rothblatt, through a family trust, exercised 9,500 stock options at $135.42 per share and subsequently sold 9,500 common shares at weighted average prices between $518 and $525 on August 20, 2026. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted in November 2025. After these transactions, the trust retains 94,410 stock options from the grant, and Rothblatt holds additional direct and indirect common shares.
United Therapeutics (UTHR) legal chief sells 8,300 shares
Paul A. Mahon, EVP & General Counsel of United Therapeutics Corp (UTHR), exercised stock options for 8,300 shares and subsequently sold all 8,300 shares in multiple open-market transactions on August 20, 2026. These transactions, executed under a pre-arranged Rule 10b5-1 plan established in August 2025, involved an exercise price of $146.03 per share and sales prices ranging from approximately $520.03 to $527.21 per share. After the transactions, Mahon holds 64,140 stock options and 45,172 common stock shares directly.
United Therapeutics (NASDAQ: UTHR) CEO trades under 1,734,410-option 10b5-1 plan
Martine A. Rothblatt, Chairperson & CEO of United Therapeutics (UTHR), through family trusts, exercised 9,500 stock options at $135.42 per share and simultaneously sold these 9,500 shares in open-market transactions ranging from $522 to $536 per share. These transactions, generating an approximate pre-tax spread of $3.72 million, were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. The plan allows for the exercise of up to 1,734,410 stock options expiring on March 15, 2027, or until December 31, 2026.
